MarginsXMarginsX
Home › Markets › Health Care › VTGN

Vistagen Therapeutics Inc. (VTGN)

VTGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1843
+2.11% on the day
Market cap
$8.5M
Nano cap
Revenue · 2025
$1.3M
+161.1% on 2024
Net income · 2025
-$69.7M
-5491.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1411685/000162828026043271/0001628280-26-043271-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-03-31.

Profile

FieldValue
TickerVTGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001411685
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$1.3M
Net income-$69.7M
Operating income-$72.1M
Net margin-5491.3%
Operating margin-5683.7%
Revenue growth+161.1%
Cash$30.8M
Total assets$48.6M
P/E (computed)Net income was not positive
P/S (computed)6.7×

Warning signs

Cash runway
3.3 months
$17.0M cash at June 30, 2026
Share count, 1 year
+16.9%
2025-11-12 to 2026-11-10 · +70.9% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"When substantial doubt exists under this methodology, management evaluates whether the mitigating effects of its plans sufficiently alleviate substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$17.0M cash; operating cash flow -$15.6M a quarter.Report 2026-06-30
Shares outstanding46,186,049 (2026-11-10); 39,495,451 a year earlier; 27,023,038 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-05
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-07-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-06-30
$1.5M-$13.0M-$14.7M$17.0M$0$2.5M10-Q 2026-08-14
Q4 2026
2026-03-31
$465K-$16.3M-$16.2M$30.8M$192K$1.3M10-K 2026-06-15
Q3 2026
2025-12-31
$303K-$18.9M-$17.6M$47.4M$379K$790K10-Q 2026-02-12
Q2 2026
2025-09-30
$258K-$19.4M-$13.8M$62.8M$658K$721K10-Q 2025-11-13
Q1 2026
2025-06-30
$244K-$15.1M-$18.8M$49.0M$933K$646K10-Q 2026-08-14
Q4 2025
2025-03-31
-$15K-$13.6M-$10.1M$67.1M$0$486K10-K 2026-06-15
Q3 2025
2024-12-31
$234K-$14.1M-$10.3M$74.7MNo debt tags$698K10-Q 2026-02-12
Q2 2025
2024-09-30
$183K-$13.0M-$10.9M$84.2MNo debt tags$875K10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-06-17
Latest annual report10-K2026-06-15
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-07-31

Source: SEC EDGAR submissions feed, 913 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+12.5%
1 month-14.3%
3 months-33.3%
Year to date-72.7%
1 year-95.3%
From 52-week high-96.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CALCCalciMedica Inc.$1.19-1.65%$8.2M
MTVAMetaVia Inc.$1.21-7.31%$8.1M
PHIOPhio Pharmaceuticals Corp.$0.7522-2.44%$9.0M
BFRGBullfrog AI Holdings Inc.$0.4878-9.92%$9.0M
RKTORocket One Inc.$0.3210+0.03%$8.0M
ENSCEnsysce Biosciences Inc.$0.4095-2.13%$8.0M
GDTCCytoMed Therapeutics Limited$0.7739-6.68%$9.2M
LEXXLexaria Bioscience Corp.$4.41-0.68%$9.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier